Related Experiment Videos
Long-term treatment with 'Duovent' in elderly patients affected by chronic obstructive lung disease
Respiration; International Review of Thoracic Diseases
|January 1, 1986
Summary
Duovent, a combination of fenoterol and ipratropium bromide, effectively improved lung function and symptoms in elderly patients with chronic obstructive lung disease over 12 weeks. The treatment showed no significant adverse cardiovascular effects or tolerance issues.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Chronic obstructive lung disease (COPD) is a progressive condition characterized by persistent respiratory symptoms and airflow limitation.
- Effective bronchodilator therapy is crucial for managing COPD symptoms and improving lung function.
Purpose of the Study:
- To evaluate the efficacy and safety of Duovent (fenoterol + ipratropium bromide) in elderly patients with COPD.
- To assess the impact of Duovent on clinical symptoms and objective measures of bronchial obstruction.
Main Methods:
- A 12-week treatment study involving twelve COPD patients over 60 years old.
- Regular clinical assessments and measurement of pulmonary function indices including FEV1, VC, RV, and sGaw every 14 days.
Main Results:
- Significant improvements in clinical symptoms were observed.
- Concurrent significant improvements in functional parameters such as FEV1, VC, RV, and sGaw indicated enhanced bronchial patency.
- No adverse cardiovascular effects, significant side-effects, or development of drug tolerance were reported.
Conclusions:
- Duovent demonstrates a favorable efficacy and safety profile for the treatment of elderly COPD patients.
- The combination therapy effectively alleviates symptoms and improves lung function without significant adverse events or tolerance.